Proteomic identification of new biomarkers and application in thyroid cytology

Acta Cytologica

Volumn 50, Issue 5, 2006, Pages 518-528

  Torres Cabala, Carlos ^a   Bibbo, Marluce ^b   Panizo Santos, Angel ^a   Barazi, Heba ^a   Krutzsch, Henry ^a   Roberts, David D ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Aspiration biopsy, fine needle; Proteomics; Tumor markers; Tumor, thyroid

Indexed keywords

GALECTIN 1; GALECTIN 3; PROTEIN S 100; PROTEIN S 100C; PROTEOME; TUMOR MARKER; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ARTICLE; ASPIRATION BIOPSY; CELL NUCLEUS; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FROZEN SECTION; GOITER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRODISSECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEOMICS; THYROID CARCINOMA; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; THYROID PAPILLARY CARCINOMA; UNITED STATES; VALIDATION PROCESS;

EID: 33749010892     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000326006     Document Type: Article

References (45)

1. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice: Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. Diagn Cytopathol 1996;15:84-89
2. Belfiore A, La Rosa GL: Fine-needle aspiration biopsy of the thyroid. Endocrinol Metab Clin North Am 2001;30:361-400
3. Rosai J, Carcangiu ML, De Lellis RA: Tumors of the thyroid gland. In Atlas of Tumor Pathology. Third series, fascicle 5. Edited by J Rosai, LH Sobin LH. Armed Forces Institute of Pathology, Washington, DC, 1992, pp 49-62
4. Oertel YC, Oertel JE: Thyroid cytology and histology. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:541-557
5. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A: Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-3502
6. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650
7. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: Personalized molecular medicine. JAMA 2001;14;286:2211-2214
8. Pandey A, Mann M: Proteomics to study genes and genomes. Nature 2000;15:405:837-846
9. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y, Steeg PS: Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002;15;62:6740-6749
10. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002;2:76-84
11. Torres-Cabala C, Panizo-Santos A, Krutzsch HC, Barazi H, Namba M, Sakaguchi M, Roberts DD, Merino MJ: Differential expression of S100C in thyroid lesions. Int J Surg Pathol 2004;12:107-115
12. Hernandez JD, Baum LG: Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002;12:127R-236R
13. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB, Fusco A: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 1995;64:171-175
14. Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors: Potential diagnostic implications. Am J Pathol 1995;147:815-822
15. Lloyd RV: Distinguishing benign from malignant thyroid lesions: Galectin 3 as the latest candidate. Endocr Pathol 2001;12:255-257
16. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002;87:4806-4810
17. Bartolazzi A, Bussolati G: Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2006;48:212-213
18. Allen BG, Durussel I, Walsh MP, Cox JA: Characterization of the Ca2+-binding properties of calgizzarin (S100C) isolated from chicken gizzard smooth muscle. Biochem Cell Biol 1996;74:687-694
19. Sakaguchi M, Yamada H, Tsuji T, Inoue Y, Miyazaki M, Tanaka T, Namba M: Loss of nuclear localization of the S100C protein in immortalized human fibroblasts. Radiat Res 2001;155:208-214
20. Yoo BC, Fountoulakis M, Cairns N, Lubec G: Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 2001;22:172-179
21. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y: Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol 2001;152:237-250
22. Shimizu S, Narita M, Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999;399:483-487
23. Caraci P, Aversa S, Mussa A, Pancani G, Ondolo C, Conticello S: Role of fine-needle aspiration biopsy and frozen-section evaluation in the surgical management of thyroid nodules. Br J Surg 2002;89:797-801
24. Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002;26:366-372
25. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr: Proteomics in early detection of cancer. Clin Chem 2001;47:1901-1911
26. Craven RA, Totty N, Harnden P, Selby PJ, Banks RE: Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: Evaluation of tissue preparation and sample limitations. Am J Pathol 2002;160:815-822
27. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713
28. Paron I, D'Ambrosio C, Scaloni A, Berlingieri MT, Pallante PL, Fusco A, Bivi N, Tell G, Damante G: A differential proteomic approach to identify proteins associated with thyroid cell transformation. J Mol Endocrinol 2005;34:199-207
29. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T: Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-2484
30. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J: Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 1998;18A:2637-2641
31. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998;58:3015-3020
32. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronovo V, Sanjuan X, Cardesa A, Liu FT, Sobel ME: Galectin-3 and laminin expression in neoplastic and nonneoplastic thyroid tissue. J Pathol 1997;181:80-86
33. Cvejic D, Savin S, Golubovic S, Paunovic I, Tatic S, Havelka M: Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: Possible relation to tumour progression. Histopathology 2000;37:530-535
34. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD: Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2002;87:4792-4796
35. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997;113:1906-1915
36. van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367
37. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635-4640
38. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G, Tell G: Nuclear localization of galectin-3 in transformed thyroid cells: A role in transcriptional regulation. Biochem Biophys Res Commun 2003;302:545-553
39. Lin HM, Pestell RG, Raz A, Kim HR: Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002;21:8001-8010
40. Sakaguchi M, Miyazaki M, Inoue Y, Tsuji T, Kouchi H, Tanaka T, Yamada H, Namba M: Relationship between contact inhibition and intranuclear S100C of normal human fibroblasts. J Cell Biol 2000;149:1193-1206
41. Inada H, Naka M, Tanaka T, Davey GE, Heizmann C: Human S100A11 exhibits differential steady-state RNA levels in various tissues and a distinct subcellular localization. Biochem Biophys Res Commun 1999;263:135-138
42. Johannessen JV, Sobrinho-SimoesM: The fine structure of follicular thyroid adenomas. Am J Clin Pathol 1982;78:299-310
43. Stefaneanu L, Tasca C: An electron-microscopic study of human thyroid cancer. Endocrinologie 1979;17:233-239
44. Sarikaya A, Huseyinova G, Irfanoglu ME, Erkmen N, Cermik TF, Berkarda S: The relationship between 99Tc(m)-sestamibi uptake and ultrastructural cell types of thyroid tumours. Nucl Med Commun 2001;22:39-44
45. Le Mellay V, Troppmair J, Benz R, Rapp UR: Negative regulation of mitochondrial VDAC channels by C-Raf kinase. BMC Cell Biol 2002;3:14